已收盘 12-12 16:00:00 美东时间
-0.060
-1.44%
Rimini Street (RMNI) repurchased 975,000 shares in Q4 2025 for $3.8M at an average price of $3.92, reducing outstanding shares by ~1.1%. The company has completed $13.3M in repurchases under its $50M ...
12-02 00:12
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and
11-18 22:07
今日重点评级关注:康托·菲茨杰拉德:维持Cabaletta Bio"超配"评级,目标价从15美元升至30美元;HC Wainwright & Co.:维持Invivyd"买入"评级,目标价从5美元升至10美元
11-03 20:20
Rimini Street shares are trading lower after the company reported worse-than-ex...
10-31 21:27
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Rimini Street 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** 第三季度营收1.034亿美元,同比下降1.2%。剔除Oracle PeopleSoft服务收入后,核心业务营收同比增长2.5%。国际业务占总营收的55%,美国业务占45%。 **盈利能力:** 毛利率为59.9%,较去年同期的60.7%有所下降。Non-GAAP毛利率为60.4%,低于去年同期的61.1%。净利润方面,GAAP净利润为280万美元(每股0.03美元),而去年同期为净亏损(每股-0.47美元)。Non-GAA
10-31 12:31
Rimini Street (NASDAQ:RMNI) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.09 by 18.6 percent. This is a 68.18 percent decrease over earnings of $0.22 per share from the
10-31 04:03
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
今日重点评级关注:花旗:维持Arcus Biosciences"买入"评级,目标价从47美元升至54美元;HC Wainwright & Co.:上调Karyopharm Therapeutics评级至"买入",目标价15美元
10-14 09:56
LUCID CAPITAL MARKETS analyst Alex Fuhrman initiates coverage on Rimini Street (NASDAQ:RMNI) with a Buy rating and announces Price Target of $6.
10-13 22:03
Rimini Street (NASDAQ:RMNI) repurchased a total of 891,000 shares of common stock for about $3.8 million with an average per share purchase price of $4.22, reducing around 1% of shares outstanding as ...
09-11 21:54